Skip to main content
. 2021 Apr 19;31(10):7512–7522. doi: 10.1007/s00330-021-07905-x

Table 3.

Complications in the overall and in the matched population

Overall population Matched population
Lipiodol-TACE, n = 160 DEB-TACE, n = 167 Lipiodol-TACE, n = 101 DEB-TACE, n = 101
Abdominal pain
Grade 1–2 4 (2.5) 0 2 (2) 0
Grade 3–4 0 0 0 0
Grade 5 0 0 0 0
Nausea/vomiting
Grade 1–2 5 (3.1) 0 1 (1) 0
Grade 3–4 1 (0.6) 0 1 (1) 0
Grade 5 0 0 0 0
Fever
Grade 1–2 8 (5) 5 (3) 6 (6) 4 (4)
Grade 3–4 0 1 (0.6) 0 0
Grade 5 0 0 0 0
Liver dysfunction
Grade 1–2 21 (13.1) 3 (1.8) 13 (12.9) 3 (3)
Grade 3–4 0 0 0 0
Grade 5 0 0 0 0
Other*
Grade 1–2 4 (2.5)* 6 (3.6)° 3 (3)+ 2 (2)^
Grade 3–4 3 (1.9)** 6 (3.6)°° 1 (1)++ 2 (2)^^
Grade 5 1 (0.6)*** 0 0 0

Data are given as numbers (and percentages)

Other complications included:

*Cholecystitis, hyperglycemia, pleural effusion; vasovagal syndrome

**Cholecystitis, pleural effusion, respiratory failure

***Liver abscess and liver failure

°Transient renal failure, cholecystitis, pleural effusion, pancreatitis, hyperglycemia, allergy to contrast media

°°Abscess formation (n = 2), pancreatitis (n = 2), cholecystitis; groin hematoma

+Cholecystitis, vasovagal syndrome, pleural effusion

++ Pleural effusion

^ Transient renal failure, allergy to contrast media

^^ Groin hematoma, pancreatitis